Reversal Dabigatran Anticoagulant Effect With Idarucizumab
NCT02815670
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemorrhage
Interventions
DRUG:
Idarucizumab
Sponsor
Boehringer Ingelheim